Silas Inman | Authors

September 12, 2022

Findings from the phase 3 CodeBreaK 200 trial show improved progression-free survival with sotorasib vs docetaxel in previously treated KRAS G12C-mutant non–small cell lung cancer.

September 11, 2022

Patients with advanced clear cell renal cell carcinoma given lenvatinib plus pembrolizumab had sustained overall survival and progression-free survival benefit vs sunitinib, according to updated results of the CLEAR trial.

September 11, 2022

Results from a blood-based multi-cancer detection test potentially indicated the presence of cancer.

September 10, 2022

Long-term results of a phase 2 study (NCT02211131) revealed consistent efficacy at 5 years with talimogene laherparepvec in stage IIIB to IVM1a melanoma.

September 10, 2022

Results of a phase 3 study appear to indicate better progression-free and overall survival outcomes with camrelizumab and rivoceranib vs sorafenib in unresectable hepatocellular carcinoma.

September 10, 2022

A randomized phase 3 trial presented at 2022 ESMO revealed better progression-free survival outcomes with tumor-infiltrating lymphocytes vs ipilimumab in stage IIIC/IV unresectable, treatment-refractory melanoma.

June 11, 2022

Treatment with the oral VEGFR2 inhibitor rivoceranib appears to induce responses in recurrent or metastatic adenoid cystic carcinoma.

June 09, 2022

Patients with very high-risk renal cell carcinoma experienced a notable relapse-free survival benefit vs placebo following treatment with everolimus.

June 07, 2022

Radiotherapy can be avoided after surgery in certain patients with low-grade luminal A breast cancer who have low Ki67 expression and no positive lymph nodes, according to data from 2022 ASCO.

June 05, 2022

The phase 3 DESTINY-Breast04 trial using fam-trastuzumab deruxtecan-nxki showed a reduction in the risk of disease recurrence or death for patients with HER2-low, hormone receptor–positive metastatic breast cancer.